Department of Neuroscience, Norwegian University of Science and Technology
Trondheim, Norway
NCT Number: NCT02019017
Cluster headache is an intense and powerful, one-sided headache accompanied by involuntary symptoms such as red eye, droopy eyelids, flow of tears, small pupils and one-sided facial sweating. The headache is believed to be the most intense of all headaches and among many is totally disabling and of great personal and social consequences. For a small group of patients with episodic and most chronic form, drug therapy has little effect. For them, surgery can be a solution.
Neuroradiology has found evidence of a possible original activation of cluster headache from the portion of the brain called hypothalamus. Furthermore, an activation of the parasympathetic nervous system through the sphenopalatine ganglion, which may also explain some of the one-sided involuntary symptoms, is suspected in cluster headache. Injection of Botulinum toxin type A (BTA) inhibits secretion of synaptic acetylcholine resulting in nerve signals being blocked. The duration of such a blockade is believed to be 3-9 months.
The purpose of the present study is to develop and evaluate a new surgical procedure with injection of BTA for blocking of the sphenopalatine ganglion. The goal is to relieve the symptoms of refractory cluster headache with a minimal invasive procedure.
The main objective of the project is to determine the safety of BTA injection in the area of the sphenopalatine ganglion of refractory cluster headache and detect the adverse events. Secondary objectives are to identify the changes of headache attacks by the method used.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1 / Phase 2
Trondheim, Norway
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Botox
Other names: Botox
Time frame: For the follow-up period of 6 months
Number of adverse events and number of participants with adverse events after BTA injection in the area of the sphenopalatine ganglion and severity of adverse events. Registration of any adverse events categorized by probable relationship to drug, the surgical procedure or anesthesia. Data obtained from the headache diaries as well as open questions during consultations.
Time frame: Average number of attacks of baseline compared to average of week 3 and 4 after injection
Time frame: Average of baseline compared to average of week 3 and 4 after injection
Time frame: Average of baseline compared to average of week 3 and 4 after injection
Norwegian University of Science and Technology
Other
Endoscopic Block of the Sphenopalatine Ganglion With Botulinum Toxin in Intractable Cluster Headache - Safety Issues
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06011811
Brain Diseases, Central Nervous System Diseases
Houston, Texas, United States
View Trial DetailsNCT05264714
Brain Diseases, Central Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT00329836
Brain Diseases, Central Nervous System Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05023460
Brain Diseases, Central Nervous System Diseases
Aarhus N, Denmark
View Trial Details